The US Supreme Court's Myriad decision satisfied both patient groups and patent holders
A UC Berkeley survey provides insight into biopharma's risk concerns and strategies.
An integrated focus on product design, development, operation, and control.
In this article, the author reviews some of the techniques that can yield valuable information on protein stability, focusing specifically on protein aggregation. Emphasis is placed on the enhanced information made available when technologies are used orthogonally, and the alignment of different approaches with specific stages of the biopharmaceutical development workflow.
Viruses in animal-derived starting materials could contaminate biopharmaceutical final product. A rigorous testing strategy and removal methods are reviewed.
The authors provide common misconceptions and key concepts behind reliability engineering.
The authors describe the growth characteristics of human mesenchymal stem cells cultured in a stirred-tank bioreactor.
A simple, sensitive, and universal platform for identification and quantification of trace-level protein impurities in biotherapeutics is described.
This article is the third and final in a series designed to offer leaders and managers at all levels in the industry a road map to excellence in human performance and human error prevention.
Can postapproval FDA filings immunize pharma companies from patent lawsuits?
Successful management of the CMO/client relationship should include open communication and trust.
In this question-and-answer discussion of "generic" biologics, the authors contend small changes in manufacturing of biologics dramatically affect the safety and efficacy of the therapeutic molecule.
The move to single-use manufacturing has prompted a paradigm shift in facility design.
A simple, sensitive, and universal platform for identification and quantification of trace-level protein impurities in biotherapeutics is described.
Traditional project decision-making vs. a QbD approach.
A new downstream purification platform using a salt-tolerant membrane adsorber.
Advances in cell culture media technology have helped achieve safer biologics.
Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.
The authors describe a new assembly for bulk and final drug product filling operations.
Operational planning and early cost analyses are key to generating optimal, robust, and economical commercial processes.
The authors describe a novel means to control ice nucleation using a sterile cryogenic ice fog.
The authors describe a simple method to remove endotoxins from highly viscous formulations.
A novel approach to sterile drug product manufacturing uses a single-use assembly in a multi-product final filling suite with isolator technology.
Webinar Date/Time: Thu, Sep 5, 2024 11:00 AM EDT
Reauthorization of pediatric exclusivity provisions looms in 2012 and debates begin anew.